drugset / Trial / NCT00335452

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

NCT00335452

Phase 3 Completed 25086 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

Timeline

Start
2006-06
Primary completion
2009-09
Completion
2009-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylsalicyclic acid Unknown 75 mg Oral
Subject Acetylsalicyclic acid Unknown 100 mg Oral
Subject Acetylsalicyclic acid Unknown 300 mg Oral
Subject Acetylsalicyclic acid Unknown 325 mg Oral
Subject Clopidogrel Small molecule 75 mg Oral